Novel methods for prediciting and treating tumors resistant to drug, immunotherapy and radiation
AssigneeThe Regents of the University of California
InventorsValerie M. WEAVER, Kun-Chih Kelvin Tsai
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for prognosis, diagnosis, and treatment of malignant tumors that were treatment resistant. The present invention provides methods of prognosis and diagnosis of multidrug resistant tumors through detection of the expression levels of nuclear co-repressor 2 (“N-CoR2”), histone deacetylases 3 (“HDAC3”), and their associated gene expression biomarkers. The present invention also provides methods of sensitizing tumors to anti-tumor therapeutics by disrupting HDAC3 activation, abrogating the N-CoR2-HDAC3 interaction, inhibiting the activity of either protein, or by downregulating the expression of either protein.
Claims20
A method of diagnosing a treatment resistant tumor in a subject, the method comprising the steps of:
- (a) analyzing a tumor sample from the subject with an assay that specifically detects a marker selected from the group consisting of N-CoR2, and MK167;
- (b) determining whether or not the markers are differentially expressed (over or under expressed);
- and
- (c) determining if the differential expression correlates with a multidrug resistance signature, thereby providing a diagnosis for a treatment resistant tumor.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of providing a prognosis for a malignant tumor after treatments, the method comprising the steps of:
- (a) analyzing a tumor sample from a subject with an assay that specifically detects a marker selected from the group consisting of N-CoR2, and MK167;
- (b) determining whether or not the markers are differentially expressed (over or under expressed);
- and
- (c) determining if the differential expression correlates with a multidrug resistance signature, thereby providing a prognosis for a malignant tumor.
(canceled)
A method of providing a prognosis for the response of a malignant tumor to preoperative anti-tumor therapeutics, the method comprising the steps of:
- (a) analyzing a tumor sample from the subject with an assay that specifically detects a marker or probe selected from the group consisting of N-CoR2, and MK167;
- (b) determining whether or not the markers are differentially expressed (over or under expressed);
- and
- (c) determining if the differential expression correlates with a multidrug resistance signature, thereby providing a prognosis for the response of a tumor to preoperative anti-tumor therapeutics.
-21. (canceled)
-25. (canceled)
Dependencies are inferred from the claim text.